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Summary
Background—A core outcomes set (COS) is an agreed minimum set of outcomes that should be 
measured and reported in all clinical trials for a specific condition. Hidradenitis suppurativa (HS) 
has no agreed-upon COS. A central aspect in the COS development process is to identify a set of 
candidate outcome domains from a long list of items. Our long list had been developed from 
patient interviews, a systematic review of the literature and a healthcare professional survey, and 
initial votes had been cast in two e-Delphi surveys. In this manuscript, we describe two in-person 
consensus meetings of Delphi participants designed to ensure an inclusive approach to generation 
of domains from related items.
Objectives—To consider which items from a long list of candidate items to exclude and which to 
cluster into outcome domains.
Methods—The study used an international and multistakeholder approach, involving patients, 
dermatologists, surgeons, the pharmaceutical industry and medical regulators. The study format 
was a combination of formal presentations, small group work based on nominal group theory and 
a subsequent online confirmation survey.
Results—Forty-one individuals from 13 countries and four continents participated. Nine items 
were excluded and there was consensus to propose seven domains: disease course, physical signs, 
HS-specific quality of life, satisfaction, symptoms, pain and global assessments.
Conclusions—The HISTORIC consensus meetings I and II will be followed by further e-Delphi 
rounds to finalize the core domain set, building on the work of the in-person consensus meetings.
Introduction
Development of evidence-based and consensus-driven outcome measures is necessary to 
ensure that study results are comparable, to permit meta-analyses and hence better inform 
healthcare decisions. As a consequence, consensus on outcomes is a prerequisite for patients 
to receive the benefits of top-level evidence-based medicine. Hidradenitis suppurativa (HS) 
is a chronic, inflammatory skin disease, characterized by repeated outbreaks of painful 
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inflamed nodules or boils in the apocrine-gland-bearing regions (axillae, genital area, groin, 
breasts and perianal region).1,2 The estimated prevalence is 1–4% worldwide.3–5 HS is 
associated with significant disability due to pain and subsequent loss of mobility.6 
Interventions for HS are diverse and include topical treatment, systemic antibiotics, anti-
inflammatory therapy, biologics and surgical therapy including laser surgery.7 There is a 
need for continuing research on therapies, as the level of evidence for existing treatments is 
low, suggesting a particular need for trials.8
Clinical trials should have well-defined primary and secondary outcomes to answer 
questions generated by the main hypotheses. A core outcomes set (COS) is an agreed 
minimum set of outcomes that should be measured and reported in all clinical trials of a 
specific disease or trial population, a recommendation of what should be measured and 
reported in all clinical trials.9 Once a COS is defined, the next step is to achieve consensus 
on the instruments most suitable to measure each core domain.10 This selection process 
includes evaluation of the quality of the instruments, assessing their validity, reliability, 
responsiveness to change and feasibility.11
Like most diseases, HS has no agreed-upon COS, and the reported outcome measurement 
instruments are numerous. In a recent systematic review, the authors identified a total of 30 
outcome measure instruments in 12 randomized controlled trials, and the quality of studies 
looking at the validity of the instruments was generally low.12 Consequently, trialists and 
researchers use various instruments, which may or may not be representative of the most 
important aspects of the disease. In addition, the heterogeneity and lack of consensus 
regarding use of outcome measure instruments limits the possibility to perform evidence 
synthesis, including meta-analysis,8 and likely leads to outcome reporting bias because of 
selective reporting of more favourable outcomes. Empirical evidence of this phenomenon 
has been highlighted in the literature.13
Based on these existing problems within HS outcome measures, the HIdradenitis 
SuppuraTiva cORe outcomes set International Collaboration (HISTORIC) was formed as a 
collaboration between the International Dermatology Outcome Measures (IDEOM) 
initiative, the Cochrane Skin Group – Core Outcome Set Initiative, and Zealand University 
Hospital, Roskilde.
The first HISTORIC goal was to develop a COS for HS clinical trials, reducing the risk of 
heterogeneity in instruments and outcome reporting bias and ensuring that researchers report 
on outcomes that are relevant to all major stakeholders.14,15 The intention is that the COS 
for efficacy measures should help guide all HS clinical trials on a global basis, covering both 
medical and surgical trials.
A central aspect in the COS development process is to identify a list of candidate items from 
which domains can be developed. It is strongly recommended that the views of all relevant 
stakeholders are heard in this process.14,15 An effective way of ensuring that the initial list of 
candidate items is important to the whole community of stakeholders, including patients, is 
to incorporate qualitative research into the development process.16 For our COS process the 
generation of items by patients was based on qualitative studies conducted in both Denmark 
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and North America as a mixture of individual and focus-group interviews until the point of 
saturation.17
Results from the qualitative studies were combined with the results of a systematic review of 
relevant literature and an online healthcare professional (HCP) item-generation survey to 
generate one combined list of candidate items. In the process of combining and analysing 
the results of the three data-sets, the steering group realized that some important decisions 
needed to be taken, in particular how to combine related items into broader domains. It was 
decided that a wider set of HS stakeholders should have the chance to vote by e-Delphi on 
56 nominal items to help guide formation of candidate domains.
After the first two e-Delphi rounds the Delphi participants were invited to take part in two 
consensus meetings, at which patients and HCPs worked side by side, together with 
members of the steering committee, to combine the nominated items into domains, informed 
by the results of the first two e-Delphi rounds. The meetings were followed by an online 
confirmation survey. Our method permitted inclusion of opinions from a wide set of patients 
and other Delphi participants in the important phase of domain formation from candidate 
items. The consensus meetings took place in September and October 2016 in Vienna and 
New York, respectively, and the results of these and the confirmation survey are reported 
here.
The aims of the first consensus meeting were to (i) review the results of the first two e-
Delphi rounds, (ii) discuss whether any items could be removed from the list of potential 
items, (iii) discuss grouping of items into domains and (iv) discuss appropriate names for the 
created domains.
The aim of the second consensus meeting was to obtain a North American perspective on the 
same four points including the results of the first meeting. Specific questions addressed 
were: (i) Should any items excluded at the first meeting be retained? (ii) Do all items fit in 
their domains? (iii) Should any combined items form their own domain? (iv) Is the name for 
each domain appropriate?
The aim of the subsequent online confirmation survey was to gain confirmation from the 
larger HISTORIC project group for decisions taken at the meetings before implementation.
Materials and methods
Initial steps
An overview of our COS development methodology highlighting the contribution of the in-
person consensus meetings can be found in Figure 1. Initiatives including Core Outcome 
Measures in Effectiveness Trials (COMET), Outcome Measures in Rheumatology 
(OMERACT)18 and Harmonizing Outcome Measures for Eczema (HOME)10 provided 
methodological guidance that was used and adapted by HISTORIC. Prior to the current 
study, a list of 56 candidate items was identified as described in the introduction. More 
details for these initial phases can be found in our COS development protocol.17
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In brief, the e-Delphi exercise involved 94 participants (42 patients with HS and 52 HCPs) 
from 19 countries across four continents. In the first two Delphi rounds, participants voted 
on an unsorted list of candidate items in terms of their importance in being measured as 
outcomes in all future HS trials. The results of the first two rounds were then used to inform 
the structure of two consensus meetings, which are reported here.
Study design
The study was international and multiprofessional involving patients, dermatologists, 
dermatological surgeons, industry representatives and drug regulatory authorities. The study 
took place at two face-to-face consensus meetings in Vienna and New York with a following 
online confirmation survey. The meeting locations were planned for both Europe and North 
America to ensure that European and North American patient and HCP opinions from both 
continents were incorporated. The meetings were planned by the HISTORIC steering group, 
consisting of researchers, HS clinicians and a patient research partner.17
Meeting participants
All Delphi participants from the e-Delphi surveys were invited to attend either the first or the 
second meeting. If attendance in person was not possible, they were invited to join the 
Vienna meeting via a Skype® connection. Identification and purposive sampling of the e-
Delphi participants is described in the study protocol.17 A few additional individuals who 
had shown an interest in joining the initiative were invited to take part in the second meeting. 
Our aim was to maintain a 1 : 1 ratio of patients to HCPs if possible.
Study procedures
An overview of the study procedures can be found in Figure 2. Both consensus meetings had 
the same overall structure, but differed slightly in the required tasks. Tasks for the first 
meeting were ranking of the items in order of priority, identifying items that could be 
excluded, grouping of the remaining items into domains, and ranking of domains in order of 
priority. The participants of the second meeting were asked to mirror the first by considering 
whether any excluded items should be retained, checking whether the participants agreed 
with the item combinations that were put forward by the first meeting to form domains, and 
considering whether the domain names were appropriate.
The structure consisted of initial formal presentations, followed by small group work and 
subsequent plenary sessions, based on nominal group theory.19 The spoken language was 
English. Introductory presentations included a description of the HISTORIC collaboration, a 
summary of the need for a COS for HS clinical trials, and results from the first two rounds 
of the e-Delphi.17 Background information about how the candidate items were identified 
was also provided, together with an introduction to the small group work designed to 
generate consensus using nominal group theory. It was stressed that the views of all 
participants at the meeting, both patients and HCPs, were of equal importance.
The introductory presentations were followed by a series of small group sessions (six in the 
first meeting and three in the second meeting). During each session, two small groups 
worked independently and in parallel, supervised by neutral facilitators. Both facilitators 
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were medical doctors and PhD students studying HS, who were not voting in the e-Delphi 
surveys. The neutral facilitators encouraged contributions from quieter group members. 
Group members were switched between each session to ensure that different combinations 
of patients and HCPs were formed; however, each small group contained at least two 
patients so that HCPs did not dominate the discussion.
Physical cards, one for each item, were placed on the table for each small group to provide a 
visual aid for the discussion. On the front of each card was the name and a description of an 
item and on the reverse side were summary statistics of the votes cast for the item in the 
preceding e-Delphi exercise, subdivided by patients and HCPs. Each small group session 
lasted 20–40 min.
Results from each of the two small groups were presented to all participants in subsequent 
plenary sessions, stimulating discussion if there were differences between the groups. 
Consensus was sought by discussion, and if consensus was not possible then no decision 
was imposed. In particular, when discussion involved an item for possible exclusion, if no 
consensus was reached then the item was retained.
As only a subset of the e-Delphi group was able to attend the in-person meetings because of 
the global locations of HISTORIC participants, discussion was not followed by binding 
voting. Instead all decisions taken at the meetings required confirmation by the larger 
HISTORIC project group in a subsequent online confirmation survey sent to all participants. 
A summary of the discussion was provided in the survey together with the results, and 
participants were asked if they agreed with exclusion of the nominated items, if they thought 
all items fitted in the created domains, if any of the combined items should form their own 
domain and if each domain name was appropriate. Consensus for implementation was 
defined as > 70% of each stakeholder group voting in agreement with the decision. Further 
information on the methodology applied to the confirmation survey and the following e-
Delphi rounds is described in the study protocol.17
Results
Participants
A list of study participants subdivided by stakeholder group, country and sex can be found in 
Table S1 (see Supporting Information).
The HISTORIC consensus meeting I had 19 participants (five patients, 14 HCPs) from 11 
countries across four continents, the majority being European. The HISTORIC consensus 
meeting II had 25 participants (six patients, 19 HCPs), the majority being North American.
The 11 participating patients with HS represented six different patient organizations. One 
additional Canadian patient participated in the first meeting via a Skype® connection. The 
participating HCPs were dermatologists (n = 14), dermatological surgeons (n = 5), U.S. 
Food and Drug Administration (FDA) representatives (n = 2), pharmaceutical industry 
representatives (n = 2), epidemiologists (n = 3) and nonvoting (in e-Delphi) steering group 
members or facilitators (n = 4). For comparison, the 52 HCPs included in the e-Delphi round 
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one were dermatologists (n = 41), dermatological surgeons (n = 5), medical regulators (n = 
1), nurses (n = 4) and pharmaceutical industry representatives (n = 1).
Excluded items
The comprehensive list of unsorted items (n = 57) that the participants evaluated is shown in 
Table S2 (see Supporting Information). Nine items were marked for exclusion during 
HISTORIC consensus meeting I, due to either lack of relevance, being unrelated to 
measurement of disease severity, or not being directly linked to the disease (Table S3; see 
Supporting Information). Some participating HCPs spoke in favour of excluding coping, itch 
and fatigue, but the participating patients did not approve and the items were retained.
At the HISTORIC meeting II, there was consensus that all of the items identified at the first 
meeting were appropriately designated for exclusion. However, it was agreed that the 
biomarker item should be marked as an area of specific future research interest. It was noted 
that if, in the future, a biomarker is proven to be strongly related to disease activity or 
treatment response then the biomarker item or domain should be reconsidered for inclusion 
in the core domain set.
Grouping of items into domains and naming of domains
Creation of potential domains was achieved by small group and plenary sessions at the 
HISTORIC consensus meeting I, producing consensus to group the items into nine domains 
(Table S4; see Supporting Information). These domains and their contributing items were 
reviewed at the HISTORIC consensus meeting II. HISTORIC consensus meeting II 
participants recommended switching the ‘number of chronic areas’ item from the ‘physical 
signs’ domain to the ‘disease course’ domain, as the item would be reported by the patient 
rather than being measured by the physician. It was highlighted that the term ‘chronic’ in 
this context needs to be defined further and this issue was marked as a future task for the 
HISTORIC project. The group provisionally agreed that ‘chronic’ relates to a duration of ≥ 6 
weeks.
Both working groups at consensus meeting II independently agreed to rename the 
‘decreased mobility’ item as ‘physical functioning’ and to combine this domain with the 
‘psychological–social’ domain to form an ‘HS-specific quality of life’ domain. Participants 
emphasized that it is crucial that this domain should capture the specific aspects of the 
patient's quality of life that are affected by HS, so a generic health-related quality-of-life 
domain would not be sufficient.
Another recommendation from meeting II was to group together the ‘patient global 
assessment’ and ‘physician global assessment’ domains to produce a single ‘global 
assessment’ domain encompassing both the patient and HCP perspectives. This fusion and 
the global assessment items and domains themselves were heavily debated. Some 
participants felt that the global assessments should be excluded altogether because, by 
definition, global assessment provides a relatively nonspecific overview of disease severity. 
Others spoke in favour of global assessments because they considered a global anchor to be 
very useful. Another argument in favour of retaining global assessments is that these 
domains are considered important by the FDA. Creation of a single ‘global assessment’ 
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domain was suggested by a group member and supported by the rest of the group based on 
the concept that both the patient and HCP global perspectives are important and should be 
assessed in a similar manner.
After HISTORIC consensus meeting II, there was consensus to suggest seven core domains: 
disease course, physical signs, HS-specific quality of life, satisfaction, symptoms, pain and 
global assessments (Table S5; see Supporting Information).
Consensus meeting online confirmation survey
Nearly all decisions taken at the meetings were confirmed by > 70% of each stakeholder 
group. The only exception was confirmation of the name for the created domain 
‘satisfaction’ which was confirmed by only 61% of HCPs. This domain therefore needed 
adjustment.
Discussion
In total, 41 stakeholders including patients, dermatologists, dermatological surgeons, 
epidemiologists, statisticians, pharmaceutical industry representatives and drug regulatory 
representatives participated in the HISTORIC consensus meetings I and II. Important 
progress was made towards reaching global consensus on core outcomes for HS clinical 
trials. Seven potential core domains were put forward for consideration by the larger e-
Delphi consensus group in subsequent e-Delphi surveys.
Our study differs from other COS processes in that our domains were developed through in-
person discussion, combining items from a comprehensive list of candidate items. This 
discussion was guided by votes cast in preceding e-Delphi surveys. In most previous studies, 
domains are created by the steering committee alone without broader dialogue with Delphi 
participants before the first round of the Delphi survey is launched. The concept of involving 
more patients and other Delphi participants in the creation of the domains is based on the 
principle of inclusivity, in keeping with the philosophy of our HISTORIC initiative. 
Feedback from stakeholders was very positive and the general view was that an inclusive 
approach is important to ensure relevance to patients and subsequent global acceptance and 
use of the HS COS by clinical trial designers.
One methodological limitation is that it was not possible to have all e-Delphi participants 
present at the meetings, and therefore it was not possible to incorporate everyone's opinion 
in the formation of domains. To address this issue, the next step will be to ask the larger e-
Delphi group if they agree with the decisions made at the meetings in an evaluation and 
confirmation survey. After this, the next planned steps are to perform two additional e-
Delphi rounds. The results from these rounds will finalize the core domain set, having built 
on the work from our in-person consensus meetings.
Another limitation to the study is that we did not achieve our aim of a 1 : 1 ratio of 
participating patients and HCPs. However, the meeting facilitators did ensure that the 
patients provided equal input to the HCPs, even though they were outnumbered by the 
HCPs, by encouraging patient involvement in every aspect of the discussion.
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With the present study, we have come a lot closer to global consensus on a COS for HS 
research. The number of randomized controlled trials of HS therapy is still limited. 
However, interest in the disease is growing and the number of trials planned is considerable. 
The development of a COS is thus particularly timely for HS, and an HS COS should 
substantially improve future HS trial design.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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What's already known about this topic?
• Reported outcome measure instruments for hidradenitis suppurativa (HS) are 
numerous and diverse, with 30 instruments recently found in 12 randomized 
trials.
• This diverse use of instruments limits the possibility to perform evidence 
synthesis and may produce outcome reporting bias.
• A core outcomes set (COS) is an agreed minimum set of outcomes that 
should be measured and reported in all clinical trials.
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What does this study add?
• The study used an international and multistakeholder approach, involving 
patients, dermatologists, surgeons, the pharmaceutical industry and medical 
regulators.
• Two consensus meetings, in Europe and North America, considered potential 
HS core domains, within a nominal group theory structure.
• Seven potential core domains were put forward to the subsequent e-Delphi: 
disease course, physical signs, HS-specific quality of life, satisfaction, 
symptoms, pain and global assessments.
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What are the clinical implications of this work?
• The development of a COS is particularly timely for HS and should 
substantially improve future HS trial design.
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Fig 1. 
Summary of the hidradenitis suppurativa core domain development process, highlighting 
(circle) the part described in this study. HCP, healthcare professional.
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Fig 2. 
Summary of the study procedures. COS, core outcomes set.
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